These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28497422)

  • 1. Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.
    Li F; Huang J; Ji D; Meng Q; Wang C; Chen S; Wang X; Zhu Z; Jiang C; Shi Y; Liu S; Li C
    Clin Transl Oncol; 2017 Oct; 19(10):1283-1291. PubMed ID: 28497422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
    Chen S; Zhao J; Cui L; Liu Y
    Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.
    Zhang H; He B; Cui J; Zhao M; Zhang Z
    Cancer Biomark; 2018; 23(3):427-436. PubMed ID: 30223392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.
    Wang X; Meng Q; Wang C; Li F; Zhu Z; Liu S; Shi Y; Huang J; Chen S; Li C
    Biomarkers; 2017 Nov; 22(7):654-660. PubMed ID: 27998182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.
    Xie F; Li P; Gong J; Tan H; Ma J
    Clin Transl Oncol; 2018 May; 20(5):591-598. PubMed ID: 28956302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis.
    Jia J; Huang B; Zhuang Z; Chen S
    Int J Biol Markers; 2018 May; 33(2):222-230. PubMed ID: 29712496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
    Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
    J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
    Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
    Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
    Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.
    Ma M; Shi C; Qian J; Teng J; Zhong H; Han B
    Gene; 2016 Oct; 591(1):58-64. PubMed ID: 27370697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.